Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Already cleared in the US for use in soft tissue ablation, Pulse Biosciences is looking to add AF to CellFX’s indication list ...

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...

MIAMI - Pulse Biosciences, Inc. (NASDAQ:PLSE), a biotech company with a market capitalization of $1.08 billion and an ...

As an academic cardiologist, I cherish our combined mission of providing outstanding care to patients, advancing care through research and educating the next generation.